Clinical Trial

Real World-clinical Outcomes of Tucatinib, Trastuzumab, and Capecitabine Following Trastuzumab Deruxtecan (T-DXd) for the Treatment of HER2-positive Metastatic Breast Cancer.

Completed
View on ClinicalTrials.gov →
Summary
A retrospective study of de-identified (to preserve patient privacy) patient information from the Flatiron Health Database to describe 3L and 4L real-world (rw) outcomes (e.g. time to next treatment, time to discontinuation, and overal survival) of the tucatinib-trastuzumab-capecitabine triplet therapy immediately following T-DXd therapy in patients diagnosed with HER2+ metastatic breast cancer (mBC) in the United States.
Protocol Amendment History 9 amendments
This ClinicalTrials.gov record has been amended 9 times since 2025-04-29; most recent amendment 2026-01-07.
Status change: Active, Not Recruiting → Completed 2025-11-14
Status change: Not Yet Recruiting → Active, Not Recruiting 2025-06-10
Trial Details
NCT Number NCT06961331
Lead Sponsor Pfizer
Conditions Metastatic HER2+ Advanced Breast Cancer
Enrollment 86 participants
Start Date 2025-05-07
Primary Completion 2025-09-25 (estimated)
Study Completion 2025-09-25 (estimated)
Updated on ClinicalTrials.gov 2026-01-09